International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

It's Time for a New Philosophy

Author(s): Brunner Scott

Issue: Sep/Oct 2021 - Volume 25, Number 5
View All Articles in Issue

Page(s): 386-387

Download in electronic PDF format for $75

Abstract:

Related Keywords: Scott Brunner, CAE, U.S. Food and Drug Administration, FDA, drug supply chains, covid-19 pandemic, temporary guidance, labeling standards, registration of 503A compounding pharmacies, adverse event reporting

Related Categories: BUSINESS, LEGAL, ADVERSE DRUG EVENTS

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
It's Time for a New Philosophy Brunner Scott	Sep/Oct 2021 Pg. 386-387
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic McElhiney Linda F	Jul/Aug 2020 Pg. 287-295
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Allowing Compounding Pharmacies to Address Drug Shortages Broughel James	Mar/Apr 2022 Pg. 100-109
A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot Brunner Scott	Jul/Aug 2021 Pg. 296-297
PreScription: COVID-19 and Compounding Pharmacists Allen Loyd V Jr	Jul/Aug 2020 Pg. 268
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B	Mar/Apr 2021 Pg. 109-113
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Riepl Mike	Jan/Feb 2023 Pg. 12-21
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
U.S. Food and Drug Administration Takes Aim (Again) at Animal Compounding: Draft Guidance for Industry #256 Lacks Authority, Will Increase Costs, and Put Pets at Risk Brunner Scott	May/Jun 2020 Pg. 198-199
International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance Miller David G	Nov/Dec 2015 Pg. 449-450
FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows Brunner Scott	May/Jun 2021 Pg. 206-209
Return to Top